ALNYLAM PHARMACEUTICALS, INC.
Last · NasdaqGS$229.40+4.925 (+2.20%)live · yahoo · 1h ago
Market cap$30.70B133.8M sh
P/E · TTM38.6fwd 18.4 · eps 5.95
Beta0.27vs S&P 500
Div yield0.00%annual · TTM
52w range
$197.81$495.55
Volume367.6Ksession
| Revenue | $4.8B |
|---|---|
| Operating income | $999.8M |
| Net income | $808.0M |
| Free cash flow | $793.9M |
| Operating margin | 20.8% |
| Net margin | 16.8% |
| Return on equity | 59.7% |
| Period | TTM 2026-06-30 |
Loading chart…
OpenFilings analyst
Our analyst
From latest 10-K · 2026-02-12
- Amvuttra Concentration
- Rna Interference Pipeline
- First Profitability
- Sanofi Royalties
- Customer Concentration
- Attr Competition
- Convertible Debt
Red flags
- AMVUTTRA generated $2.31 billion, approximately 77% of 2025 net product revenue of $2.99 billion; the company explicitly states that future results depend on sustaining and growing AMVUTTRA sales.
- Distributor A represented 45% of consolidated revenue in 2025, up from 29% in 2024, indicating substantial customer concentration.
- Sanofi royalties on global AMVUTTRA sales range from 15% to 30%, with the top 30% tier applying to annual sales above $1.50 billion; this structurally limits gross-margin expansion.
- The company still had an accumulated deficit of $6.70 billion despite 2025 net income of $314 million, and expects operating results to fluctuate materially.
- The $661.3 million of 0.00% convertible notes due 2028 and other convertible debt create potential future cash settlement, refinancing or dilution exposure.
Upcoming earnings
1:30 PM UTC+1
Period
Sep 2026
Est. EPS
$2.27
Est. revenue
1.4B
Earnings transcripts
Documents
FormReporting forFiledFlags